# Safety and Efficacy of Nemolizumab in PN

> **NCT03181503** · PHASE2 · COMPLETED · sponsor: **Galderma R&D** · enrollment: 70 (actual)

## Conditions studied

- Prurigo Nodularis

## Interventions

- **DRUG:** CD14152 Dose A
- **DRUG:** CD14152 placebo

## Key facts

- **NCT ID:** NCT03181503
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-02
- **Primary completion:** 2018-09-26
- **Final completion:** 2018-09-26
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2020-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03181503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03181503, "Safety and Efficacy of Nemolizumab in PN". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03181503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*